Eisai Opens Parenteral Facility in NC

Eisai, Inc. has opened its newly constructed parenteral facility in Research Triangle Park (RTP), NC. The 65,000-sq.-ft. facility will serve as the company’s global commercial manufacturing and drug development site for intravenous drug products in support of global clinical development programs, including those for oncology. The $100 million facility encompasses aseptic processing suites, labs and other support functions. The new operation is also designed to handle and process highly potent compounds utilizing isolator containment technology.

“Eisai is committed to developing novel anti-cancer agents and other treatments as part of its human health care mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide,” said Haruo Naito, president and chief executive officer, Eisai Co. “The opening of this new facility marks a major milestone in our history and will support the advancement of important new therapies for patients, especially those who are battling life-threatening illnesses.”

The company recently submitted regulatory applications for approval of an investigational agent for the potential treatment of locally advanced or metastatic breast cancer, to agencies in Japan, the U.S. and the EU. If approved, this drug may be the first oncology product manufactured at Eisai’s new parenteral facility.